drugset / Trial / NCT06763965
Evaluating the Safety and Efficacy of BioTTT001 in Patients With Recurrent/Progressive High-grade Glioma.
Phase 1/2
Enrolling by invitation
30 enrolled
Beijing Bio-Targeting Therapeutics Technology Co., Ltd
NaSingle-groupOpen-labelTreatment
Summary
This study is a single-arm, open-label, dose-escalation and dose-expanding Phase Ⅰb/Ⅱ clinical study to evaluate the safety, tolerability, biodistribution characteristics and preliminary efficacy of recombinant human nsIL12 oncolytic adenovirus injection (BioTTT001) in patients with recurrent/progressive high-grade glioma.
Timeline
- Start
- 2024-11-26
- Primary completion
- 2027-07-31
- Completion
- 2027-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BioTTT001 | Unknown | 1e+10 unknown | Other |
| Subject | BioTTT001 | Unknown | 5e+10 unknown | Other |
| Subject | BioTTT001 | Unknown | 2.5e+11 unknown | Other |